Business Context and Reporting Period
This Form 8-K is filed by Ocuphire Pharma, Inc. (formerly Rexahn Pharmaceuticals, Inc.) on November 20, 2020, reporting events occurring on November 19, 2020. The filing details the issuance of warrants pursuant to a Pre-Merger Financing agreement completed in connection with the company's business combination on November 5, 2020.
Key Financial Metrics and Capital Structure
The filing does not provide revenue, profit, cash flow, or margin data. It focuses on capital structure changes resulting from the Pre-Merger Financing, which raised an aggregate purchase price of approximately $21.15 million. As of November 5, 2020, there were 10,841,870 shares of Common Stock outstanding.
- Series A Warrants Issued: 5,665,838 shares exercisable at $4.4795 per share; immediately exercisable with a 5-year term.
- Series B Warrants Issued: 665,837 shares exercisable at $0.0001 per share; immediately exercisable with an expiration tied to the Reservation Date or full exercise.
- Escrow Release: Approximately 3,749,992 shares of Common Stock (Converted Additional Shares) were delivered to investors on November 19, 2020.
Material Changes
The primary material change is the issuance of Series A and Series B Warrants to accredited investors on November 19, 2020, fulfilling obligations under the Amended and Restated Securities Purchase Agreement dated June 29, 2020. This issuance follows the delivery of escrowed shares and represents a significant increase in potential dilution and outstanding equity instruments.
Guidance, Risks, and Unusual Items
The filing contains no forward-looking guidance, management commentary on operations, or discussion of liquidity risks. The transaction was executed as an unregistered sale of equity securities in reliance on the exemption under Section 4(a)(2) of the Securities Act, based on investor representations of accredited status.
Investor Verification Checklist
- Verify the total number of shares underlying the Series A and Series B Warrants against the company's latest cap table.
- Confirm the exercise price and expiration terms of the Series A Warrants ($4.4795, 5-year term).
- Review the definition of the "Reservation Date" to determine the expiration timeline for Series B Warrants.
- Check the definitive proxy statement filed on October 2, 2020, for the complete text of the warrant agreements referenced in this filing.